Search PubMed⌕ Search

Biomedical subjects

K Wilms

Publications and source records attributed to K Wilms.

At least 73 records · Page 4Linked to original sources
PubMed1981

[Bone marrow transplantation in acute leukemias: antibody treatment for suppression of graft-versus-host disease (author's transl)].

Anti-human-thymocyte globulin (AHTZG) was applied to prevent GvHD in clinical bone marrow transplantation. AHTZG produced by absorption with several cell preparations reacted specifically with T-lymphocyte populations and was no longer inhibitory to human CFUc and bone marrow growth in diffusion chambers. Marrow grafts of 14 patients with ALL were incubated in vitro with AHTZG and transferred to the recipients conditioned with antileukemic chemotherapy and total body irradiation of 1000 rad. Ten patients were transplanted after relapse, four patients during remission. The patients tolerated the marrow without side effects and a hemopoietic engraftment was seen in 12 cases. Three patients showed signs of GvHD on the skin, two of them showed later on also manifestations in the liver. In the other cases no GvHD could be detected. Five out of 14 patients are still alive between 144 and 964 days post transplantation in remission.

Acute Disease↗
PubMed1981

[Unusual course in 2 patients with testicular teratoma during vinblastine-cyclophosphamide chemotherapy].

Two patients with metastatic embryonal testicular cancer achieved complete remission receiving a vinblastine-cyclophosphamide combination chemotherapy. After a previous treatment with vinblastine-bleomycin one patient had developed progressive disease, the other one had attained partial remission only. Because of our own experiences and because of the results in single agent chemotherapy this well tolerated vinblastine-cyclophosphamide combination is proposed as maintenance therapy for testicular teratoma. Other maintenance therapies according to the literature and the problem of maintenance therapy in general are discussed.

Adult↗
PubMed1980

[The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].

A sensitive reproducible, nondestructive method for the determination of adriamycin and its metabolites in plasma, leukocytes and tissues has been developed. Apolar substances as adriamycinone (adm-one) were extracted at pH 2 with chloroform, polar ones as adriamycin (adm) and adriamycinol (adm-ol) at pH 8.8 with chloroform: methanol, separated by thin-layer-chromatography and quantitated by fluorescence spectrophotometry. The plasma levels of adm-ol and adm-one were lower in all patients compared to those of adm. Further metabolites were found in the bile. Toxic effects were found in patients with prolonged half-lives in the elimination phase. A delayed elimination was observed in a patient with an elevation of the bilirubin level, but also in patients without overt liver disease. The pharmacokinetics of adm showed considerable inter- and intraindividual fluctuations.

Chromatography, Thin Layer↗
PubMed1980

[Lymphocytosis].

Explore the source record for details and available documents.

Humans↗
PubMed1980

[Long-term survival of adults with acute leukemia [author's transl)].

Seven patients with acute leukemia, 20 to 49 years old, survived 4 years or more. Three patients are in complete remission after 9 1/2, 5 1/2, and 4 10/12 years. One patient has been in second complete remission for 20 months after the first remission lasting almost 12 years. One patient relapsed after 37 months duration of complete remission, two other patients died after 6 3/4 and 4 1/4 years survival. All patients demonstrated at the beginning of leukemia aleukemic courses, normal or slightly decreased platelet counts, small tumor masses, and were free of severe infections. Cytochemical findings, blast counts in bone marrow and peripheral blood, drug programs, and duration of induction treatments, however, were no prognostic parameters for longterm remission.

Acute Disease↗
PubMed1979

[Severe megaloblastic anaemia by triamterene in a patient with alcoholic liver cirrhosis (author's transl)].

Mucosal ulceration and severe bone-marrow insufficiency with marked megaloblastic transformation occurred during treatment with triamterene in a patient with decompensated alcoholic liver cirrhosis and malnutrition. When the triamterene-containing preparation was stopped and folinic acid administered the haematological picture improved, but the patient died, with signs of hepatocellular insufficiency, of gastro-intestinal bleeding. The serum folic-acid level was markedly reduced due to the chronic malnutrition, while the vitamin B12 level was within normal limits. This observation indicates that when the pool of folic-acid coenzymes is reduced, triamterene can cause megaloblastic anaemia due to its folic-acid antagonism. Triamterene should, therefore, be given to patients with borderline folic-acid reservoirs, chronic alcoholism or during pregnancy, only under careful serial control of the blood picture.

Anemia, Macrocytic↗
PubMed1979

[Further purification of a tissue specific inhibitor in lymphopoiesis (lymphocyte chalone?) (author's transl)].

A partially purified calf spleen extract, which exhibits the properties of a lymphocyte chalone (tissue-specific, species non-specific, non-toxic and reversible acting, endogenous inhibitor of cell proliferation) as concerning biological activities, has been described earlier. This fraction has been further purified by ion exchange chromatography with DEAE-Sephacel to a 10,000-fold purification. The most active fraction inhibited 3H-thymidine incorporation into phytohemagglutinin- or pokeweed-mitogen-stimulated lymphocytes by 86% resp. 70%, when given in a concentration of 100 ng/ml. Ehrlich-ascites-cells were not inhibited by the same concentration. The inhibiting activity is compared to other published lymphocyte inhibitors.

Animals↗
PubMed1979

Tissue-specific inhibitor of lymphocyte proliferation extracted and purified from calf spleen. Biological and chemical properties.

A partly purified calf spleen extract which inhibits lymphocyte proliferation in a tissue-specific, species-nonspecific, nontoxic, and reversible way, and may thus contain a chalone-like activity, has been further characterized. Our results show that the inhibitor works in G1-phase. The activity is resistant to heat, trypsin- and ribonuclease-treatment. It appears to be an acidic molecule and it does not appear to contain ribonucleic acid. These properties are compared to the characteristics which have been described for tissue-specific inhibitors of lymphocyte proliferation by other authors.

Animals↗
PubMed1978

[A modified MOPP regimen in the treatment of Hodgkin's disease stage III B and IV (author's transl)].

In a retrospective study 80 patients with Hodgkin's disease of stage III B (n = 32) and IV (n = 48) were investigated, who had been treated with a modified MOPP regimen. 28 patients (35%) were previously untreated. A completed remission was reached in 51 patients, a partial remission in 16, and 13 patients failed to respond. 16 patients had died in the observation period. Complete remissions were twice as frequent with 90% in stage III as compared with 45% in stage IV. The group of patients surviving 4 years was 92% in stage III and 62% in stage IV.

Adolescent↗
PubMed1978

Classification of leukemic cells by Ia alloantigens and complement receptors. Surface probes for cell differentiation.

Of particular interest in the study of cell membrane markers of leukemic cells were cytotoxic and immunofluorescent results obtained in comparing Ia alloantigen and complement receptor (CR) expression on normal leukocytic and leukemic cell types. Using discontinuous Ficoll gradients, Ia alloantigens were found on varying numbers of leukemic myelo- and lymphoblasts, and on the early stages of normal melocytes. Ia alloantigens, however, were not detectable on mature polymorphonuclear cells. This establishes human Ia alloantigens as cell surface differentiation markers. The appearance of complement receptors was observed later than that of Ia alloantigens. CR1 (EAC1-4b) showed up later in the differentiation than CR2 (EAC1-3d). Thus, an immunological discrimination between AML blasts and CML blast crisis blasts appears to be possible: AML blasts are mostly Ia-positive but CR-negative, whilst CML blast crisis cells are only 20-30% Ia-positive and carry complement receptors in at least equal amounts. The AML blast cell would appear as the less-differentiated cell type when compared to the CML blast crisis cells. The picture, however, remains complex since in CML blast crisis at least three different types of blast cells can be identified: an Ia-positive and an Ia-negative myeloid blast as well as an Ia-positive lymphoid blast. The quantitative composition of these three elements within the myeloid differentiation profile can vary somewhat from patient to patient. Furthermore, these studies revealed a disturbed differentiation of leukemic cell types.

B-Lymphocytes↗